BIOMAT Database Logo BIOMAT Database Logo

Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. 2011

Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Department of Chemistry, Tsinghua University, Beijing 100084, PR China; The Guangdong Provincial Key Laboratory of Chemical Biology, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China.

Multi-target EGFR, VEGFR-2 and PDGFR inhibitors are highly useful anticancer agents with improved therapeutic efficacies. In this work, we used two virtual screening methods, support vector machines (SVM) and molecular docking, to identify a novel series of benzimidazole derivatives, 2-aryl benzimidazole compounds, as multi-target EGFR, VEGFR-2 and PDGFR inhibitors. 2-Aryl benzimidazole compounds were synthesized and their biological activities against a tumor cell line HepG-2 and specific kinases were evaluated. Among these compounds, compounds 5a and 5e exhibited high cytotoxicity against HepG-2 cells with IC₅₀ values at ∼2 μM. Further kinase assay study showed that compound 5a have good EGFR inhibitory activity and moderate VEGFR-2 and PDGFR inhibitory activities, while 5e have moderate EGFR inhibitory activity and slightly weaker VEGFR-2 and PDGFR inhibitory activities. Molecular docking analysis suggested that compound 5a more tightly interacts with EGFR and PDGFR than compound 5e. Our study discovered a novel series of benzimidazole derivatives as multi-target EGFR, VEGFR-2 and PDGFR kinases inhibitors.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017479 Receptors, Platelet-Derived Growth Factor Specific receptors on cell membranes that react with PLATELET-DERIVED GROWTH FACTOR, its analogs, or antagonists. The alpha PDGF receptor (RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA) and the beta PDGF receptor (RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA) are the two principle types of PDGF receptors. Activation of the protein-tyrosine kinase activity of the receptors occurs by ligand-induced dimerization or heterodimerization of PDGF receptor types. PDGF Receptors,Platelet-Derived Growth Factor Receptors,Receptors, PDGF,PDGF Receptor,Platelet-Derived Growth Factor Receptor,Platelet Derived Growth Factor Receptor,Platelet Derived Growth Factor Receptors,Receptor, PDGF,Receptors, Platelet Derived Growth Factor
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors.
March 2019, Bioorganic & medicinal chemistry,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
January 2014, European journal of medicinal chemistry,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
[VEGFR inhibitor (multi-target kinase inhibitors)].
February 2015, Nihon rinsho. Japanese journal of clinical medicine,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors.
January 2019, Frontiers in chemistry,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Novel benzimidazole analogs as inhibitors of EGFR tyrosine kinase.
October 2012, Chemical biology & drug design,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
February 2016, European journal of medicinal chemistry,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors.
December 2023, Journal of enzyme inhibition and medicinal chemistry,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Discovery of novel picolinamide-based derivatives as novel VEGFR-2 kinase inhibitors: synthesis, in vitro biological evaluation and molecular docking.
June 2018, MedChemComm,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
January 2017, European journal of medicinal chemistry,
Yunqi Li, and Chunyan Tan, and Chunmei Gao, and Cunlong Zhang, and Xudong Luan, and Xiaowu Chen, and Hongxia Liu, and Yuzong Chen, and Yuyang Jiang
Benzimidazole derivatives as kinase inhibitors.
January 2014, Current medicinal chemistry,
Copied contents to your clipboard!